Latest news with #qualifiedinvestors
Yahoo
3 days ago
- Business
- Yahoo
AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the Ongoing Rights Issue
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, WITHIN OR INTO THE AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES, RUSSIAN FEDERATION, BELARUS, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE CONTRAVENING TO ANY APPLICABLE RULES. ADDITIONAL RESTRICTIONS ARE APPLICABLE, PLEASE SEE "IMPORTANT INFORMATION" IN THE END OF THIS PRESS RELEASE. STOCKHOLM, SE / / July 16, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB ("AlzeCure" or the "Company") has received additional subscription commitments of SEK 7 million from a group of qualified investors in the Company's ongoing rights issue announced on June 16, 2025 (the "Rights Issue"). Should the issue be oversubscribed, the Company intends to utilize the remaining portion of the Over-Allotment Option, following the previously announced additional subscription commitment, to accommodate these subscriptions to the greatest extent possible. In addition to previously entered subscription commitments, a group of qualified investors have committed to subscribe for shares amounting to approximately SEK 7 million, corresponding to about 14 percent of the Rights Issue. The subscription commitments are based on the same terms as for other investors, i.e. no remuneration. In the event the issue is oversubscribed and the allocation under these additional subscription commitments cannot be fully allocated, the Company intends to utilize the remaining portion of the Over-Allotment Option of around SEK 5 million to accommodate theses subscription to the greatest extent possible in accordance with the principle that allocation under the overallotment option shall primarily be made to strategic and/or qualified investors. Following these additional subscription commitments, the total amount of subscription commitments entered into amounts to approximately SEK 32 million, corresponding to around 66 percent of the total amount of the Rights Issue of approximately SEK 48.5 million, with an over-allotment option of SEK 10 million. "At AlzeCure Pharma, we are very pleased with the interest and support we are seeing for the share issue, both from existing major shareholders and new investors. This demonstrates confidence in the share issue and the plans it is intended to finance, which primarily include preparations for the upcoming Phase 2 study in Alzheimer's patients with NeuroRestore ACD856 - a project for which we have secured funding from the European Innovation Council. We are very proud of this support, which can also be seen as a validation of the project," says Martin Jönsson, CEO of AlzeCure. Additional subscription commitments: Investor Subscription commitment, SEK Jan Poulsen 2,000,000 Niklas Estensson 1,000,000 Christian Månsson 1,000,000 Rose-Marie Karlsson 1,000,000 Alexander Schoeneck 1,000,000 AV Linbo Invest AB 660,000 Johan Wiklund 308,000 TOTAL 6,968,000 The subscription period for the share issue runs through July 22. More information is available at: Advisors AlzeCure has engaged Zonda Partners AB and Synch Advokat AB as financial and legal advisors, respectively, in connection with the Rights Issue. In connection with the additional subscription commitment addressed in this press release, Corpura Fondkommission AB has also acted as joint bookrunner. Important information The information in this press release does not contain or constitute an offer to acquire, subscribe for, or otherwise trade in shares, subscription warrants, or other securities in AlzeCure. No action has been taken, and no actions will be taken, to permit a public offering in any jurisdiction other than Sweden. Any invitation to eligible persons to subscribe for shares in AlzeCure will only be made through the supplementary Information Document published by AlzeCure on 7 July 2025. The information in this press release may not be announced, published, or distributed, directly or indirectly, in or into Australia, Hong Kong, Japan, Canada, New Zealand, Singapore, South Africa, the United States, Belarus, Russia, South Korea, Switzerland, or any other jurisdiction where such action would be unlawful, subject to legal restrictions, or would require actions other than those required under Swedish law. Any failure to comply with these restrictions may constitute a violation of applicable securities laws. For more information, please contact Martin Jönsson, CEOTel: +46 707 86 94 About AlzeCure Pharma AB (publ) AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless. NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of Alzheimer's disease and comprises two drug candidates. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets severe pain in conditions such as osteoarthritis. AlzeCure aims to pursue its own projects through preclinical research and development through an early clinical phase, and is continually working on business development to find suitable outlicensing solutions with other pharmaceutical companies. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit Attachments AlzeCure Receives Additional Subscription Commitments of Approximately SEK 7 million in the ongoing Rights Issue SOURCE: AlzeCure Pharma View the original press release on ACCESS Newswire
Associated Press
5 days ago
- Business
- Associated Press
Levi Strauss & Co. Commences Senior Notes Offering in Europe
SAN FRANCISCO--(BUSINESS WIRE)--Jul 14, 2025-- Levi Strauss & Co. today announced that it is commencing a private placement of up to €475 million aggregate principal amount of senior notes due 2030. As of the issue date, the notes will be general unsecured senior obligations of the company and will rank equally with all of the company's other senior unsecured indebtedness. The company intends to use the net proceeds from the offering, together with cash on hand, to redeem in full its 3.375% senior notes due 2027 (the '2027 Notes') and pay fees and expenses related to the offering and the redemption of such outstanding notes. The notes are being offered pursuant only to an offering memorandum, dated July 14, 2025. The notes are not being registered under the U.S. Securities Act of 1933, as amended (the 'Securities Act'), or applicable state or foreign securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The notes will only be offered and sold to persons reasonably believed to be qualified institutional buyers in the United States pursuant to Rule 144A under the Securities Act, outside the United States pursuant to Regulation S under the Securities Act and if resident in a Member State of the European Economic Area ('EEA'), to 'qualified investors' within the meaning of Article 2(e) of Regulation 2017/1129/EU, as amended (the 'EU Prospectus Regulation') and any relevant implementing measure in each Member State of the European Economic Area and (iii) if a resident of the United Kingdom of Great Britain and Northern Ireland ('UK'), to 'qualified investor' within the meaning of the EU Prospectus Regulation as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended (the 'UK Prospectus Regulation'). This press release is for informational purposes only and statements in this press release regarding the private offering of debt securities do not constitute and shall not, in any circumstances, constitute a public offering or an invitation to the public in connection with any offer, including within the meaning of the EU Prospectus Regulation. The offering will be made pursuant to an exemption under the Securities Act, the UK Prospectus Regulation and the EU Prospectus Regulation, as implemented in the United States, the UK and the Member States of the EEA, respectively, from the requirement to produce a prospectus for offers of securities. This press release is only being distributed to, and is only directed at, persons in the UK that (i) are 'investment professionals' falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the 'Order'), (ii) are persons falling within Article 49(2)(a) to (d) ('high net worth companies, unincorporated associations, etc.') of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000, as amended) in connection with the issue or sale of any securities may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as 'Relevant Persons'). This press release is directed only at Relevant Persons and must not be acted on or relied upon by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. The offering memorandum prepared in connection with the offering has not been and will not be approved by the U.S. Securities and Exchange Commission, the UK Financial Conduct Authority or any other competent authority. This press release does not constitute a notice of redemption in respect of the 2027 Notes. Holders of the 2027 Notes are therefore urged to refer to the relevant notice of redemption (once available) for more information regarding the redemption price, record date and redemption date. Information to Distributors Manufacturer target market (MIFID II product governance; UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs or UK PRIIPs key information document (KID) has been prepared as the notes are not available to retail investors in EEA or the UK, respectively. Forward Looking StatementsView source version on CONTACT: Investor Contact: Aida Orphan Levi Strauss & Co. (415) 501-6194 [email protected] Contact: Elizabeth Owen Levi Strauss & Co. (415) 501-7777 [email protected] KEYWORD: EUROPE UNITED STATES UNITED KINGDOM NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: MANUFACTURING ONLINE RETAIL FASHION TEXTILES RETAIL SOURCE: Levi Strauss & Co. Copyright Business Wire 2025. PUB: 07/14/2025 05:15 AM/DISC: 07/14/2025 05:15 AM
Zawya
13-05-2025
- Business
- Zawya
Saudi's Axelerated Solutions sets IPO price, seeks $21mln
Axelerated Solutions for Information and Communication Technology Company has priced its initial public offering on the Saudi Stock Exchange's parallel market (Nomu) at SAR 27 ($7.2) per share. At this price, the IPO of 3 million ordinary shares, representing a 10.17% stake post-offering, could raise $21.6 million. All the offer shares will be allocated to qualified investors, with the minimum subscription pegged at 100 shares. The subscription period will run from May 15 to May 21, 2025. Value Capital Company has been appointed as the financial advisor and lead manager for the offering. Last December, the IT firm secured the approval from the Capital Market Authority (CMA) to proceed with the IPO. Headquartered in Riyadh, Axelerated Solutions provides a range of IT services and solutions. (Writing by Cleofe Maceda; editing by Seban Scaria)
